US regulatory status: approved. Molecular target: Adrenergic receptor alpha-2.
- Target
- Adrenergic receptor alpha-2
- Mechanism
- Adrenergic receptor alpha-2 agonist
pharma · Solid Tumor, Adult · Advanced Soft-tissue Sarcoma · MNPR
Monopar Therapeutics
Monopar Therapeutics drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Wilmette, USA HQ
2015 Founded
22 Employees
Public company Type
MNPR · NYSE Ticker
Company details
- Status
- Public
- HQ
- Wilmette, USA
- Founded
- 2015
- Employees
- 22
- Programs
- 4
- Drugs
- 3
- Patents
- 3
Monopar Therapeutics pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Monopar Therapeutics drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Monopar Therapeutics in public FDA and regional records.
-
Development asset linked to Monopar Therapeutics in public FDA and regional records.